A dose-finding study of nanoparticle albumin-bound paclitaxel plus cisplatin in patients with metastatic nasophyngeal carcinomas
Journal of Clinical Oncology, 2017.
6049 Background: Nanoparticle albumin-bound paclitaxel (Abraxane, ABX), is a novel formulation of paclitaxel that has proved superior efficacy compared with conventional paclitaxel in the treatment of several metastatic cancers. We undertook this trial to determine the optimal dose and to preliminarily aseess efficacy of ABX plus cisplati...More
Full Text (Upload PDF)